245 First Street
Cambridge, MA 02142
617 871 2098
Full-time employees: 204
|Mr. John P. Butler MBA||CEO, Pres & Director||1.29M||N/A||1964|
|Mr. David A. Spellman||Principal Accounting Officer, Sr. VP, CFO & Treasurer||961.92k||N/A||1976|
|Mr. Michel Dahan||Sr. VP & COO||734.73k||N/A||1979|
|Ms. Nicole R. Hadas||Sr. VP, Chief Legal Officer & Sec.||687.38k||N/A||1973|
|Dr. Steven Keith Burke||Sr. VP of R&D and Chief Medical Officer||766.57k||N/A||1961|
|Tracey Vetterick||VP of Portfolio Strategy & Corp. Admin.||N/A||N/A||N/A|
|Mercedes Carrasco||Director of Corp. Communications||N/A||N/A||N/A|
|Mr. Douglas Jermasek M.B.A.||VP of Marketing & Strategy||N/A||N/A||1961|
|Ms. Meredith Bowman||Sr. VP of People||N/A||N/A||N/A|
|Ms. Kimberly Garko||Sr. VP of Quality, Manufacturing & Pharmaceutical Devel.||N/A||N/A||N/A|
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Akebia Therapeutics, Inc.’s ISS governance QualityScore as of 1 June 2023 is 7. The pillar scores are Audit: 9; Board: 6; Shareholder rights: 8; Compensation: 8.